Thyroid Cancer Treatments

Find Thyroid Cancer Treatments

Medications for Thyroid Cancer

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Thyroid Cancer.

Found 8 Approved Drugs for Thyroid Cancer

Liothyronine

Brand Names
Cytomel, Liomny

Liothyronine

Brand Names
Cytomel, Liomny
Form: Injection, Tablet
Method of administration: Oral, Intravenous
FDA approval date: May 08, 1956
Classification: l-Triiodothyronine
CYTOMEL is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

I-131

Brand Names
Megatope, Volumex

I-131

Brand Names
Megatope, Volumex
Form: Injection, Kit
Method of administration: Oral, Intravenous
FDA approval date: August 01, 1993
MEGATOPE is indicated in adults for use in determinations of total blood and plasma volumes.

Doxil

Generic Name
DOXOrubicin

Doxil

Generic Name
DOXOrubicin
Form: Injection, Injectable
Method of administration: Intravenous, Intravitreal
FDA approval date: May 01, 1996
Classification: Anthracycline Topoisomerase Inhibitor
Doxil liposomal infusion is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy.

Sorafenib

Brand Names
Nexavar, Sorafenib Tosylate

Sorafenib

Brand Names
Nexavar, Sorafenib Tosylate
Form: Tablet
Method of administration: Oral
FDA approval date: December 20, 2005
Classification: Kinase Inhibitor
NEXAVAR is a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma.

Caprelsa

Generic Name
Vandetanib

Caprelsa

Generic Name
Vandetanib
Form: Tablet
Method of administration: Oral
FDA approval date: July 25, 2011
Classification: Kinase Inhibitor
CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. ( 1 ) Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. ( 1 )
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances